
Myomo
Founded Year
2004Stage
IPO | IPOTotal Raised
$18.83MDate of IPO
6/12/2017Market Cap
0.03BStock Price
1.22About Myomo
Myomo (NYSE MKT: MYO) is a medical device company specializing in myoelectric orthotics for people with neurological disorders. The Company's products help to restore function in individuals with neuromuscular conditions such as brachial plexus injury, traumatic brain injury, spinal cord injury, Multiple Sclerosis, ALS, and stroke. The Company's myoelectric orthosis devices, including its flagship MyoPro line, have been clinically shown to help restore the ability to complete functional tasks by enabling individuals to self-initiate and control movement of their partially paralyzed limbs by using their own muscle signals.
Myomo Patents
Myomo has filed 8 patents.
The 3 most popular patent topics include:
- Neurotrauma
- Actuators
- Aircraft instruments

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
12/13/2018 | 8/1/2023 | Neurotrauma, Stroke, Frontal lobe, Neurological disorders, Bones of the head and neck | Grant |
Application Date | 12/13/2018 |
---|---|
Grant Date | 8/1/2023 |
Title | |
Related Topics | Neurotrauma, Stroke, Frontal lobe, Neurological disorders, Bones of the head and neck |
Status | Grant |
Latest Myomo News
Sep 5, 2023
Furthermore, with technological improvements, the demand for robots is impacted by the specifications of what they are made of and their prospective uses. The introduction of superior materials, sensors and actuators, control systems, and software technologies is a result of ongoing study and development in the field of electrical and electronic engineering. These cutting-edge components have made it simpler to develop exoskeletons that are new, better, very power-efficient, self-powered, lightweight, less complicated, and portable. Exoskeleton Market: Key Takeaways The upper extremities segment to garner the highest growth Market in Asia Pacific to grow at the highest rate Increasing Prevalence of Emergency Situations across the Globe to Boost Market Growth By the Emergency Event Database EM-DAT, 387 natural disasters, and hazards took place around the world in 2022, claiming 30,704 deaths and affecting 185 million people. In emergency and rescue situations, robotics may be used in a variety of ways. A robotic exoskeleton could undoubtedly assist in the actual rescue by transporting supplies, rescuing individuals from hazardous circumstances, or just offering information about the circumstance. Exoskeletons are employed in factories to aid employees with painting. To lower tiredness and improve production, the exoskeleton enables the worker to utilize their arms with greater efficiency. Exoskeleton technology has also been shown to help welders maintain better posture and reduce muscular fatigue, which may result in fewer injuries and more production. There has been growing interest from the military from all over the world in deploying exoskeletons owing to their various advantages. Exoskeletons come equipped with sensors that let soldiers maintain tabs on their health while wearing them. Exoskeleton Market: Regional Overview The global exoskeleton market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa region. Expanding technology Industry to Drive Market Growth in the North America Region The exoskeleton market in the North American region is estimated to garner the largest revenue by the end of 2035. The growth of the region can be impelled by the growing adoption of emerging technology such as exoskeleton. Approximately 7 out of 10 people in America consider exoskeleton as a developing technology working in benefit to improve themselves and their daily activities. Moreover, there has been growing awareness regarding this emerging technology among people which is also estimated to boost market growth. Additionally, growth in the market has been aided by the presence of major industry players in the North American region and an increase in R&D efforts to introduce innovations. The North American government's large military and healthcare expenditures have also contributed to the market's growth. Growing Aging Population and Rehabilitation Needs to Propel the Growth in the Asia Pacific Region The Asia Pacific exoskeleton market is estimated to garner the highest CAGR by the end of 2035. The Asia Pacific region has a rapidly aging population, leading to an increased demand for rehabilitation solutions. Exoskeletons have been explored as assistive devices for the elderly population and those with mobility impairments. For instance, countries like Japan and South Korea have a significant elderly population, and exoskeletons have been researched as tools to help seniors maintain their mobility and independence. Asia Pacific countries are major players in the manufacturing and industrial sectors. Exoskeletons have been explored for applications such as reducing worker fatigue and preventing injuries in industries where manual labor is intensive. These applications can contribute to improved worker safety and productivity. Asian countries have been investing in research and development across various technology sectors. As exoskeleton technology evolves, research institutions and companies in the region have been working on improving the capabilities and affordability of these devices. Make an Inquiry Before Buying this Report @ Upper Extremities Amongst these segments, the upper extremities segment is anticipated to hold the largest share over the forecast period. The upper extremities segment of the exoskeleton market plays a crucial role in rehabilitation for individuals with upper limb impairments resulting from conditions such as stroke, spinal cord injuries, or neuromuscular disorders. Exoskeletons designed for upper extremity rehabilitation can assist patients in regaining movement and strength in their arms and hands, improving their quality of life. The upper extremities segment has applications in industries where manual labor and repetitive arm movements are common. Exoskeletons can assist workers in tasks that involve lifting, carrying, and using tools. This can lead to reduced fatigue and the prevention of work-related musculoskeletal disorders. Advances in materials science and engineering have enabled the development of exoskeletons that are lighter and more compact, enhancing user comfort and mobility. This trend can be measured through reductions in the weight of exoskeletons over time. Exoskeleton, Segmentation by Technology Passive Amongst these segments, the powered segment is anticipated to hold a significant share over the forecast period. Powered exoskeletons have emerged as a game-changer in the field of rehabilitation, offering a lifeline to individuals recovering from mobility-limiting conditions such as spinal cord injuries and strokes. The ability of these exoskeletons to provide targeted assistance to impaired limbs has significantly improved the prospects of recovery. Request for Customization of this Report @ According to a study by the National Spinal Cord Injury Statistical Center, there are around 17,000 new spinal cord injury cases annually in the United States alone, underscoring the considerable potential market size for rehabilitation-focused exoskeletons. With a globally aging population, the demand for assistive technologies has surged. Powered exoskeletons have risen to the occasion, enabling seniors to maintain their independence and engage in activities that might otherwise be challenging. Exoskeleton, Segmentation by Mobility Military & Defence A few of the well-known market leaders in the global exoskeleton market that are profiled by Research Nester are Myomo, Inc., Bionik, ATOUN Inc., Cyberdyne Inc., Lockheed Martin Corporation, Parker Hannifin Corporation, Mitsubishi Heavy Industries Ltd., Ekso Bionics, Daiya Industry Co. Ltd., B-Temia, and other key market players. Recent Development in the Market Myomo, Inc., the manufacturer of wearable medical robotics that increases functionality for people with neurological conditions and paralysis of the upper limbs, reports that new research evaluating the advantages of the MyoPro myoelectric orthosis it manufactures has discovered "statistically significant improvements" in several motor function measurements. B-Temia announced that the United States Food and Drug Administration has granted 510(k) clearance for their powered human mobility device Keeogo Dermoskeleton System. The greatest medical equipment market in the world is now open thanks to this clearance. About Research Nester Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach to helping global industrial players, conglomerates, and executives for their future investments while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new horizon, provided the right guidance at the right time is available through strategic minds.
Myomo Frequently Asked Questions (FAQ)
When was Myomo founded?
Myomo was founded in 2004.
Where is Myomo's headquarters?
Myomo's headquarters is located at One Broadway, Cambridge.
What is Myomo's latest funding round?
Myomo's latest funding round is IPO.
How much did Myomo raise?
Myomo raised a total of $18.83M.
Who are the investors of Myomo?
Investors of Myomo include Mountain Group Partners, Boynton Angels, Boston Harbor Angels and MIT Deshpande Center for Technological Innovation.
Who are Myomo's competitors?
Competitors of Myomo include JOGO, Monteris Medical, Endologix, NeuroSky, IlluminOss Medical and 12 more.
Compare Myomo to Competitors

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.
Axis Surgical Technologies, Inc. aims to develop, manufacture, and market devices that improve quality and efficiency in spinal surgery, especially for minimally invasive surgical techniques. Based in Mountain View, California, Axis offers an integration of visualization and articulation capabilities and provides spinal surgery equipment. Axis' FDA Grant In March 2010, Axis announced that it received 510(k) clearance from the Food and Drug Administration to market its C-MOR„ Visualization Device to use in diagnostic and operative arthroscopic and endoscopic procedures. This portable tool provides visualization and illumination of an interior cavity through either a natural or surgical opening. The ergonomic lightweight device also offers practitioners the convenience of endoscopic visualization and efficient one-handed operating ability; this device can be employed in hospital outpatient departments, ambulatory surgery centers, and office surgery suites.

Cardious is a medical device company organized to develop and commercialize the AvA Aortic Valve Bypass Graft System for use as a minimally invasive, beating heart alternative to traditional aortic valve replacement therapy.
ABS Corporation designs and develops minimally invasive technology focused on relieving pain in the knee. Two medial knee implant systems have been developed: The PEEK Mobility Medial Knee Implant and the OrthoGlide Medial Knee Implant.
FloShield is a family of products that improve visualization during laparoscopic surgery. It was founded in 2009 and is based in Cupertino, California.
NanoPowers aims to develop artificial muscles for various implant indications. The Company has developed several animal proof of concepts, and is entering preclinical stages with devices aimed for the treatment of urinary and fecal incontinences.